Soligenix, Inc.

04/20/2026

Reformulating An In-Clinic IV To At-Home Injection Puts Patients At The Center

For Soligenix, reformulation was not a detour but a necessary step toward optimizing a therapy for real-world use. Discover how the team reformulated its drug delivery from in-clinic to at-home administration.

04/06/2026

The Rare Disease Rubicon: Crossing The Chasm From Biotech To Bio-Commercial

04/02/2026

“Looking beyond science, it is ex*****on and capital discipline that ultimately determine which biotech companies will survive” via

“Looking beyond science, it is ex*****on and capital discipline that ultimately determine which biotech companies will survive”

04/02/2026

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Published in Oncology and Therapy

HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...

03/31/2026

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026 from HyBryte™ trial PRINCETON, N.J., March 31, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...

03/26/2026

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

03/19/2026

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

02/26/2026

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

02/12/2026

Soligenix Details Recent Progress and Upcoming Milestones in Shareholder Update Letter

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

12/17/2025

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J., Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a...